Jack W. Reich

Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA.

Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a private company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million.

Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million.

Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA.